Thank you for participating in the quiz!
We had a really strong response to the quiz and received positive feedback from participants including the below comments. Thank you to everyone who took part and we hope you have received, and will be using, your reward of a discount for Love My Libre products.
Very interesting. I still have a lot to learn.
The quiz was very good.
This was very interesting.
The average score was 49% and the time taken averaged 6 1/2 minutes.
We have collated the responses from the first 300 participants in order to show you the results.
The correct answers are: 1.B 2.A 3.B 4.D 5.B 6.C 7.D 8.C 9.A 10.D 11.D 12.C 13.A
For more details on the right answers please read the below comments. And if you're interested to see how others faired, you can get an idea from the below charts. The correct answer is always the one shown in green.
The first responses to this question showed that not many participants had followed this news story. However, 39% ticked 'The Queen' and got it correct but a significant number, 33% did think it may be Theresa May. Incidentally, do you know that Theresa May is a type 1 herself and uses a FreeStyle Libre?
A clear majority of 55% knew the answer was a Senseonics sensor could be implanted for up to 6 months. It is a surgical procedure currently available in the USA.
74% of participants were correct and knew that although FreeStyle Libre was launched in the UK, the availability is very limited. It is a source of frustration and misunderstanding as to why it's not more widely available to PWD in the UK.
FreeStyle Llibre 3 cannot be purchased by self-funding and has to be applied for by Consultants/Diabetes teams rather than prescribed through GPs. This approach has meant there is currently a 'postcode lottery' to getting a FreeStyle Libre 3 on the NHS.
This question shows there's a high awareness, 74%, that all type 1s should be able to get access to either a flash or CGM as standard. The only criteria that applies is that the person has type 1 diabetes, although there are still some areas adding additional criteria. This is not required by the NICE guidelines and could prevent a PWD getting standard care!
The most popular answer was that the FreeStyle Libre 3 did not give users a 12 hour grace period and this was chosen by 61% of participants.
This feature, which is available on Dexcom's latest CGM, the G7, enables users to chose a suitable time to change their sensor up to 12 hours after a sensor has expired. It gives individuals flexibility without worrying about losing data and allows use of a sensor for the full 10 day period.
Getting CGMs prescribed to PWD who are pregnant has been a huge achievement by the NHS and perhaps it surprised participants that the answer was 98% have been offered the medtech. Most quizzers chose the lowest option of 75% with 98% only chosen by 21%, in 3rd place.
A majority of 56% of participants chose the correct answer of California. There has been considerable publicity around the state's plans covered in the media. An interesting podcast explaining the plans is available for free: Click here (external link).
The Human Trial is the correct answer, not to be confused with the Diabetes Solution) which by the title could easily fit the question. Both of these films were chosen by 40% of participants.
We have recently published a review of the Human Trial. Click here to read now.
Over half of respondents, 53% chose the correct answer. The bioXensor offers lots of hope that PWD will not need to put a filament or needle into the skin to monitor glucose levels.
The answers to this question showed an almost 3-way split between the higher choices. The correct answer only narrowly chosen by the majority, 33%.
I wonder if many participants were surprised to discover that the answer to this question was an incredible $13,850 for a vial of this new preventative drug.
This question was clearly answered incorrectly as over 55% chose Novo Nordisk as the medtech manufacturer suffering a fall in share price, 27% chose the correct answer of Eli Lilly. However, this may be because Novo Nordisk is a more commonly used insulin in the UK - the country of residence of most participants in this quiz.
The majority of answers chose 3 which represented 36% of participants. This may in part be becasuse although approved for use by the NHS, unfortunately not all have been listed for use in every area. The correct answer of 4 was selected by only 19% of participants.
The four systems that are approved for use by type 1s on MDI are FreeStyle Libre 2, Dexcom ONE, GlucoMen Day and GlucoRx AiDEX.
It seems there's lots of anticipation of closed loops and most likely hope that these will become more widely available, are more easily be accessible. Over 52% had the correct answer although it's worth not ing that 31% thought it could be mental health support - perhaps this is an area that needs more resources for type 1s? There are some links to wellbeing contacts on our webpage here
We hope you were able to answer some of the questions and if you didn't score as highly as you hoped, or if you would like to keep more up-to-date with diabetes news, please do subscribe to receive emails from Libre Life.
We have recommended some reading which covers some of the topics covered in this quiz.
Below are links to the blogs and Libre Life FREE resources which expand on the topics covered.
Dexcom G7 - What to Expect. Click here
What is the Dexcom ONE CGM system? Click here
An Arm & a Leg podcast:
California plans to make its own insulin and sell it super-cheap. Really. Click here.
All information here is correct to the best of knowledge of the author at the time of publication.
Content here and on our website www.lovemylibre.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses the FreeStyle Libre 2 which is provided on NHS prescription. We do not have any affiliate relationship with Abbott FreeStyle Libre or any medtech provider. All trademarks are the intellectual property of their respective owners.